Caryn Peterson is VP at Gossamer Bio, Inc. (GOSS). They have made 5 open-market trades across 1 company since 2021, most recently 2026-01-02.
CIK 0001857256
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| GOSS | 259,333 | $2.6M |
Shares reported on the most recent Form 4, priced at the 2026-01-05 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| GOSS | SELL | 2024-03-18 | 2024-03-19 | $1.33 | $5K | -7.3% | -41.2% | -62.0% |
| GOSS | SELL | 2023-03-16 | 2023-03-20 | $1.10 | $8K | +2.5% | -15.1% | +10.5% |
| GOSS | SELL | 2022-10-24 | 2022-10-25 | $12.07 | $115K | -11.9% | -25.2% | -82.4% |
| GOSS | SELL | 2022-03-16 | 2022-03-17 | $8.28 | $104K | +1.0% | -2.4% | -31.6% |
| GOSS | SELL | 2021-10-25 | 2021-10-26 | $12.25 | $29K | +5.6% | -15.4% | -17.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.